Johnson & Johnson News

Johnson & Johnson is a large and diverse company, so staying up-to-date with developments, company performance, and their plans for the future is not easy. That's why Wiser created the Johnson & Johnson news digest. It is delivered once a day and contains the key articles from around the web in order to keep you informed. Johnson & Johnson is primarily involved in the health sector. Its interests are spread across 275 different companies in 60 countries. It was founded in 1886 and its headquarters is in New Jersey. Worldwide it employs about 128,000 people and its main consumer brands include Band-Aid, Johnson's baby products and Neutrogena. It also has a medical devices and diagnostics sector, and a pharmaceuticals sector. Challenges exist in the later, particularly regarding the competition from generic versions of some of its drugs. Its research and development pipeline is also watched with interest, as is its movements in terms of expansion - further acquisitions, particularly in the medical devices field, are expected. Make sure you do not miss any Johnson & Johnson news, analysis or information by registering for the free Wiser daily email.

Recent Johnson & Johnson News Coverage
 
Your Weekly Recommendations Tuesday, November 21, 2017
 
Recommended for you
Johnson & Johnson drug succeeds in newly diagnosed multiple myeloma patients: study
Reuters • Bill Berkrot
Johnson & Johnson: Dividend King With Good Total Return And Dividend Growth
Seeking Alpha • William Stamm
J&J reports declining spine sales in Q3 – what to expect in Q4
Becker's Spine Review • Mackenzie Garrity
Valeant: Bausch & Lomb Is #1 Contact Lenses In China E-Retailing
Seeking Alpha • Peter Tan
Anatomy of a Closing: How O'Melveny's Petrocelli Framed Winning Argument in Risperdal Bellwether
The American Lawyer • Jenna Greene
The Right Time To Buy Johnson & Johnson
Seeking Alpha • Sean Warneke
Johnson & Johnson wins California lawsuit claiming asbestos in talc caused cancer
Reuters
Johnson & Johnson hit with $247 million verdict in hip implant trial
Reuters • Tina Bellon
Achillion shares drop as J&J to sell large stake
MarketWatch • Wallacewitkowski
8 orthopedic, spine device companies who spent the most on non-research payments to Florida physicians – Zimmer Biomet leads with $4.473M
Becker's Spine Review • Mackenzie Garrity
 
Recommended for You
Cancer, Health Care Industry
Johnson & Johnson drug succeeds in newly diagnosed multiple myeloma patients: study
ReutersBill Berkrot
() - Johnson & Johnson’s blockbuster multiple myeloma drug Darzalex when added to a standard therapy regimen reduced the risk of disease progression or death by 50 percent compared with standard therapy alone in patients not previously treated for the blood cancer,...
Share
Economic Policy, Finance
Johnson & Johnson: Dividend King With Good Total Return And Dividend Growth
Seeking AlphaWilliam Stamm
Summary Johnson & Johnson total return over-performed the DOW average for my 58.0 month test period by 33.72%, which is great. Johnson & Johnson Has increased its dividend for 55 years in a row (a dividend king) and presently has a yield...
Share
Johnson & Johnson, Stryker Corp
J&J reports declining spine sales in Q3 – what to expect in Q4
Becker's Spine ReviewMackenzie Garrity
Although reporting $19.7 billion total sales in the third quarter of 2017, Johnson & Johnson's spine division saw a decline in sales, according to Market Realist. Here's what you need to know. 1. With the emergence of competitors, such as Medtronic, Zimmer...
Share
Brand Management, Health Finance
Valeant: Bausch & Lomb Is #1 Contact Lenses In China E-Retailing
Seeking AlphaPeter Tan
Summary Bausch & Lomb is the leading contact lenses brand in China, compared to Acuvue, Alcon (including CIBA Vision), and CooperVision. Bausch & Lomb is the most popular brand on Alibaba platforms - Tmall, Taobao, as well as Sigo and Kede. Bausch...
Share
Johnson & Johnson
Anatomy of a Closing: How O'Melveny's Petrocelli Framed Winning Argument in Risperdal Bellwether
The American Lawyer Jenna Greene
In the first bellwether trial in California over the anti-psychotic Risperdal, it took a Los Angeles Superior Court jury less than two hours to find for defendants Janssen Pharmaceutical and Johnson & Johnson last week. This premium content is locked for Litigation...
Share
Health Finance, Johnson & Johnson
The Right Time To Buy Johnson & Johnson
Seeking AlphaSean Warneke
Summary Impressive pharma pipeline has JNJ in a position of recognizing significant future top line growth. Based on a DCF, DDM, and comps model, JNJ is certainly not on the clearance rack, but has an enticing valuation for the benefits you get...
Share
Health Care Industry, Johnson & Johnson
Johnson & Johnson wins California lawsuit claiming asbestos in talc caused cancer
Reuters
(Reuters) - A California jury on Thursday ruled in favor of Johnson & Johnson in a lawsuit by a woman who said she developed the cancer mesothelioma after being exposed to asbestos in the company's talc-based products including J&J's Baby Powder.
Share
Education, Energy & Utilities
Johnson & Johnson hit with $247 million verdict in hip implant trial
ReutersTina Bellon
NEW YORK () - A federal jury in Dallas on Thursday ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay $247 million to six patients who said they were injured by defective Pinnacle hip implants. Delivering the third straight win...
Share
Epidemiology, Finance
Achillion shares drop as J&J to sell large stake
MarketWatchWallacewitkowski
Achillion Pharmaceuticals Inc. shares fell in the extended session Tuesday after the drug developer reported promising early data on one of its kidney-disease treatments but said a large stakeholder was selling shares in a secondary offering. Achillion shares fell 9.2% to $3.35...
Share
Hospitals, Johnson & Johnson
8 orthopedic, spine device companies who spent the most on non-research payments to Florida physicians – Zimmer Biomet leads with $4.473M
Becker's Spine ReviewMackenzie Garrity
Here are eight orthopedic and spine device companies who spend the most on non-research payments to Florida physicians, according to the Orlando Business Journal. 1. Zimmer Biomet – $4,473,263 2. Intuitive Surgical – $4,074,469 3. Stryker – $3,986,854 4. Smith & Nephew...
Share